China AI: Bernstein sees chipmakers benefiting from Nvidia scrutiny
BridgeBio Pharma Inc (NASDAQ:BBIO). has reached a notable milestone, as its stock hit a 52-week high of $40.45. This comes amid a period of strong performance, with the company’s share price reflecting an impressive 1-year change of 47.78%. According to InvestingPro data, the company’s market capitalization now stands at $7.65 billion, with analysts setting price targets as high as $95. The surge to this 52-week high underscores investor optimism and a favorable outlook for the biotech firm, which specializes in genetic disease treatment. This latest peak follows a year of strategic developments and potential advancements in BridgeBio’s pipeline, reassuring shareholders and boosting market confidence. InvestingPro analysis reveals strong financial health indicators, including a robust current ratio of 4.57 and projected revenue growth of 90% for FY2025. Discover 8 more exclusive ProTips and comprehensive analysis in the Pro Research Report, available with an InvestingPro subscription.
In other recent news, BridgeBio Pharma has reported several significant developments. Analysts from H.C. Wainwright have reiterated their Buy rating for BridgeBio, raising the price target to $56, reflecting optimism about the company’s future revenue, which is now projected to reach $423.2 million in 2025 and $637.2 million in 2026. Piper Sandler also maintained an Overweight rating, with a price target of $63, highlighting the upcoming Phase 3 CALIBRATE study for encaleret, which is expected to impact the market significantly. BMO Capital raised its price target for BridgeBio to $42 while keeping a Market Perform rating, based on anticipated strong US sales for Attruby in the second quarter of 2025.
BridgeBio’s drug acoramidis has shown promise in the ATTRibute-CM Phase 3 trial, linking increased serum TTR levels to improved survival rates in patients with transthyretin amyloid cardiomyopathy (ATTR-CM). The company has launched the ACT-EARLY clinical trial, a landmark study testing acoramidis as a preventative treatment for transthyretin amyloid disease (ATTR) in asymptomatic carriers. This trial aims to enroll about 600 participants and is a first-of-its-kind effort to prevent the onset of the disease. BridgeBio’s ongoing developments and the approval of acoramidis under the brand names Attruby™ and BEYONTTRA® in multiple regions underscore its potential impact on the ATTR-CM treatment landscape.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.